Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine, a ...

Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine-a bacterium that can cause various diseases, such as pneumonia.

Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine-a bacterium that can cause ...

Researchers at Vaxart Inc. and the Center for Vaccine Development at the University of Maryland School of Medicine evaluated ...

Vaxart (VXRT) announced that complete data from the Phase 1b trial of its first-generation oral pill norovirus vaccine candidate in elderly ...

The serum levels of inflammatory factors, including TNF-α, IL-1β and IL-2, and immunoglobulins, including immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM), were determined ...

Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.

Biohaven (BHVN) highlighted the success of BHV-1300, its potential first-in-class IgG selective degrader, in achieving rapid and deep ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...

There were no clinically significant reductions in other immunoglobulins including IgG3, IgA, IgE, or IgM compared to baseline. Based upon the rapid and deep reductions of total IgG observed with ...